Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 614-619

  Barrail Tran, A ^a   Mentre F ^b,c,d   Cosson, C ^a   Piketty, C ^e   Chazallon, C ^b   Gerard L ^b   Girard, P M ^f   Taburet, A M ^a  

^a BICÊTRE HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BICHAT HOSPITAL   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA1 GLYCOPROTEIN; ATAZANAVIR; DIDANOSINE; RITONAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; COMPARTMENT MODEL; CONCENTRATION (PARAMETERS); DRUG ABSORPTION; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; TANDEM MASS SPECTROMETRY;

ADULT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; OROSOMUCOID; PYRIDINES; SERUM ALBUMIN;

EID: 75749114468     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00797-09     Document Type: Article

References (24)

1. Barrail, A., C. Le Tiec, S. Paci-Bonaventure, V. Furlan, I. Vincent, and A. M. Taburet. 2006. Determination of amprenavir total and unbound concentrations in plasma by high-performance liquid chromatography and ultrafiltration. Ther. Drug Monit. 28:89-94.
2. Benet, L. Z., and B. A. Hoener. 2002. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 71:115-121.
3. Boffito, M., D. J. Back, T. F. Blaschke, M. Rowland, R. J. Bertz, J. G. Gerber, and V. Miller. 2003. Protein binding in antiretroviral therapies. AIDS Res. Hum Retroviruses 19:825-835.
4. Colombo, S., T. Buclin, M. Cavassini, L. A. Decosterd, A. Telenti, J. Biollaz, and C. Csajka. 2006. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50:3801-3808.
5. Colombo, S., T. Buclin, L. A. Decosterd, A. Telenti, H. Furrer, B. L. Lee, J. Biollaz, and C. B. Eap. 2006. Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodefi-ciency virus protease inhibitor clearance and cellular accumulation. Clin. Pharmacol. Ther. 80:307-318.
6. Dailly, E., O. Tribut, P. Tattevin, C. Arvieux, P. Perre, F. Raffi, and P. Jolliet. 2006. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. Eur. J. Clin. Pharmacol. 62:523-526.
7. Department of Health and Human Services. 2009. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. http://aidsinfo.nih.gov/guidelines/.
8. Duche, J. C., F. Herve, and J. P. Tillement. 1998. Study of the expression of the genetic variants of human alpha1-acid glycoprotein in healthy subjects using isoelectric focusing and immunoblotting. J. Chromatogr. B Biomed. Sci. Appl. 715:103-109.
9. Dulmer, M., G. Reker, T. T. Nguyen, L. Henke, and J. Henke. 1998. Human orosomucoid (ORM1) subtyping: further population genetic data and reports on the feasibility to type aged blood samples and stains. J. Forensic Sci. 43:413-416.
10. Eap, C. B., and P. Baumann. 1988. Isoelectric focusing of alpha-1 acid glycoprotein (orosomucoid) in immobilized pH-gradients with 8M urea: detection of its desialylated variants using an alkaline phosphatase-linked secondary antibody system. Electrophoresis 9:650-654.
11. European Medicines Agency. http://www.emea.europa.eu/humandocs/ PDFs/EPAR/reyataz/emea-combined-h494fr.pdf. Accessed 14 December 2009.
12. FDA. CDER for Reyataz. http://www.accessdata.fda.gov/drugsatfda- docs/label/2009/021567s019lbl.pdf. Accessed 14 December 2009.
13. Ford, J., S. H. Khoo, and D. J. Back. 2004. The intracellular pharmacology of antiretroviral protease inhibitors. J. Antimicrob. Chemother. 54:982-990.
14. Fournier, T., N. N. Medjoubi, and D. Porquet. 2000. Alpha-1-acid glycoprotein. Biochim. Biophys. Acta 1482:157-171.
15. Holladay, J. W., M. J. Dewey, B. B. Michniak, H. Wiltshire, D. L. Halberg, P. Weigl, Z. Liang, K. Halifax, W. E. Lindup, and D. J. Back. 2001. Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab. Dispos. 29:299-303.
16. Kremer, J. M., J. Wilting, and L. H. Janssen. 1988. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev. 40:1-47.
17. Le Tiec, C., A. Barrail, C. Goujard, and A. M. Taburet. 2005. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet. 44:1035-1050.
18. Li, J. H., J. Q. Xu, X. M. Cao, L. Ni, Y. Li, Y. Y. Zhuang, and J. B. Gong. 2002. Influence of the ORM1 phenotypes on serum unbound concentration and protein binding of quinidine. Clin. Chim. Acta 317:85-92.
19. Li, J. H., J. Q. Xu, Y. Li, Y. Y. Zhuang, and J. B. Gong. 1999. Genetic polymorphisms of orosomucoid on the Han population in Nanjing of China. Clin. Chim. Acta 288:161-168.
20. McCollam, P. L., M. A. Crouch, and P. Arnaud. 1998. Caucasian versus African-American differences in orosomucoid: potential implications for therapy. Pharmacotherapy 18:620-626.
21. Oie, S., M. A. Jacobson, and D. I. Abrams. 1993. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV). J. Acquir. Immune Defic. Syndr. 6:531-533.
22. Piketty, C., L. Gerard, C. Chazallon, A. G. Marcelin, F. Clavel, A. M. Taburet, V. Calvez, I. Madelaine-Chambrin, J. M. Molina, J. P. Aboulker, and P. M. Girard. 2006. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial. Antivir. Ther. 11:213-221.
23. Taburet, A. M., C. Piketty, C. Chazallon, I. Vincent, L. Gerard, V. Calvez, F. Clavel, J. P. Aboulker, and P. M. Girard. 2004. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48:2091-2096.
24. Wright, J. D., F. D. Boudinot, and M. R. Ujhelyi. 1996. Measurement and analysis of unbound drug concentrations. Clin. Pharmacokinet. 30:445-462.